Variables | Group I (n = 15) | Group II(n = 30) | Group III(n = 18) | P-value |
---|---|---|---|---|
BMRC stage (n, %) | 0.620 | |||
 1 | 9(60.0%) | 14(46.7%) | 12(66.7%) | |
 2 | 6(40.0%) | 14(46.7%) | 6(33.3%) | |
 3 | 0(0%) | 2(6.7%) | 0(0%) | |
Number of lumbar punctures within 10 weeks, median (IQR) | 6(4–10) | 7(6–11.25) | 7(6–8.25) | 0.143 |
CSF opening pressure, median (IQR), mmH2O | 140(115–220) | 175(128.75–232.5) | 179(135–207.5) | 0.437 |
CSF cryptococci, median (IQR), count/ml | 0(0–0) | 0(0–0.75) | 0(0–3) | 0.868 |
CSF clearance | ||||
Case (n, %) | 11(73.3%) | 22(73.3%) | 13(72.2%) | 1.000 |
 CSF white blood cell, median (IQR), *10^6/l | 8(3–22) | 16(8–48) | 19(7.5–36.5) | 0.163 |
 CSF protein, median (IQR), g/l | 0.42(0.29–0.75) | 0.62(0.36–1.31) | 0.57(0.35–1.40) | 0.310 |
 CSF glucose, median (IQR), g/l | 2.63(2.18–3.90) | 2.45(2.11–2.85) | 2.64(2.07–3.09) | 0.627 |
 CSF chloride, median (IQR), mmol/l | 122.2(120.4–125) | 121.5(117.48–125) | 122.45(121.4–126.03) | 0.407 |
Treatment Outcomes (n, %) | ||||
 Complete response | 8(53.3%) | 14(46.7%) | 11(61.1%) | 0.622 |
 Partial response | 3(20.0%) | 6(20.0%) | 2(11.1%) | 0.757 |
 Stable response | 4(26.7%) | 8(26.7%) | 5(27.8%) | 0.709 |
 Disease progression | 0(0%) | 1(3.3%) | 0(0%) | 1.000 |
 Death | 0(0%) | 1(3.3%) | 0(0%) | 1.000 |
Adverse events (n, %) | 15(100%) | 30(100%) | 18(100%) | NA |
Chills and fevers | 0(3.4%) | 2(6.7%) | 2(11.1%) | 0.565 |
Hypokalemia | 7(46.7%) | 27(90.0%) | 17(94.4%) | 0.001* |
Mild hypokalemia | 0(0%) | 6(20.0%) | 3(16.7%) | 0.188 |
Moderate hypokalemia | 6(40.0%) | 13(43.3%) | 11(61.1%) | 0.388 |
Severe hypokalemia | 1(6.7%) | 8(26.7%) | 3(16.7%) | 0.317 |
Gastrointestinal discomfort | 1(6.7%) | 15(50.0%) | 4(22.2%) | 0.008* |
Liver impairment | 6(40.0%) | 22(73.3%) | 12(66.7%) | 0.088 |
Renal impairment | 11(73.3%) | 19(63.3%) | 7(38.9%) | 0.105 |
Mild renal impairment | 6(40.0%) | 8(26.7%) | 3(16.7%) | 0.308 |
Moderate renal impairment | 4(26.7%) | 9(30.0%) | 2(11.1%) | 0.346 |
Severe renal impairment | 1(6.7%) | 2(6.7%) | 2(11.1%) | 0.844 |
Anemia | 4(26.7%) | 12(40.0%) | 7(38.9%) | 0.661 |
Phlebitis | 1(6.7%) | 2(6.7%) | 1(5.6%) | 1.000 |
Visual side effects | 1(6.7%) | 0(0%) | 0(0%) | 0.238 |